Filter Results
Clinical Studies
Results filtered:Study status:
Contact Us for the Latest Status
Closed for Enrollment
Contact Us for the Latest Status
Closed for Enrollment
-
A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease
Rochester, Minn.
The goal of the study is to compare and evaluate safety and efficacy of tesevatinib 50mg versus placebo in patients with ADPKD.
-
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Rochester, Minn.
The primary objective of this study is to determine the safety, plasma pharmacokinetics, and maximum tolerated dose (MTD) of KD019 when administered to subjects with ADPKD.
-
Long-Term Treatment and Follow Up of Subjects Completing 24 Months of Treatment with Tesevatinib on Study KD019-101 in Subjects with Autosomal Dominant Polycystic Kidney Disease
Rochester, Minn.
The purpose of this study is to assess the long term safety, tolerability, and effectiveness of tesevatinib for patients with autosomal dominant polycystic kidney disease, who started and completed 24 months of treatment for previous study KD019-101.
-
Renasight Clinical Application, Review and Evaluation (RenaCARE) Study (RenaCARE)
Rochester, Minn.
The purpose of this study is to evaluate the Renasight™ test, a next generation sequencing (NGS) gene mutation assay, for patients with chronic kidney disease (CKD) which utilizes genomic DNA from patient blood or buccal swab samples to analyze over 300 genes that are associated with autosomal dominant, autosomal recessive and X-linked disorders. Patients undergoing Renasight™ testing are offered optional genetic information sessions in addition to their test results.
.